According to a research report published by Daiwa, the mid-term revenue of CSPC Group increased by 40.1% year-on-year to 18.59 billion yuan, which is in line with previous business forecasts and expectations, higher than market forecasts; net profit of 6.1 billion yuan is also in line with the scope of the profit forecast and the forecast, and is mainly driven by license fee revenue. Product sales revenue increased 4.1% year-on-year to 12.7 billion yuan during the period, continuing the growth trend in the first quarter and in line with management's guidance on recording growth in product revenue throughout the year. The recovery in the Group's finished drug business was mainly driven by revenue growth exceeding expectations for neurological drugs. The year-on-year growth accelerated to 33.1% in the second quarter, compared to 22.2% in the first quarter. Daiwa raised its earnings forecast per share from 2026 to 2028 by 1% to 19% to reflect an increase in product sales and gross margin forecasts. The target price was raised from HK$11 to HK$11.2, maintaining a “buy” rating.

According to a research report published by Daiwa, the mid-term revenue of CSPC Group increased by 40.1% year-on-year to 18.59 billion yuan, which is in line with previous business forecasts and expectations, higher than market forecasts; net profit of 6.1 billion yuan is also in line with the scope of the profit forecast and the forecast, and is mainly driven by license fee revenue. Product sales revenue increased 4.1% year-on-year to 12.7 billion yuan during the period, continuing the growth trend in the first quarter and in line with management's guidance on recording growth in product revenue throughout the year. The recovery in the Group's finished drug business was mainly driven by revenue growth exceeding expectations for neurological drugs. The year-on-year growth accelerated to 33.1% in the second quarter, compared to 22.2% in the first quarter. Daiwa raised its earnings forecast per share from 2026 to 2028 by 1% to 19% to reflect an increase in product sales and gross margin forecasts. The target price was raised from HK$11 to HK$11.2, maintaining a “buy” rating.